Mostly true Scientifically well supported Certainty of evidence: high provisional C-INS-11

Archive conclusion: insulin is indispensable in type 1 diabetes; in type 2 diabetes, evidence supports caution with intensive dosing, prioritising metformin, weight loss and dietary change before insulin escalation, and aiming for moderate rather than near-normal HbA1c; this is not the same as rejecting insulin.

In short: This claim is mostly true. Current guidelines agree that insulin is lifelong and essential in type 1 diabetes and that in type 2 diabetes weight loss, metformin and individualised, not near-normal, targets come before insulin escalation; the archive omits that newer heart- and kidney-protective drugs are also prioritised and that insulin is needed early when glucose is very high.

Conclusion: The archive's conclusion broadly matches guidelines and contradicts the rejection of insulin.

Original statement
Scientific assessment
Scientific evidence in detail
In plain language
Studies on this claim
Regional context
What applies in my country?
References

Original statement

الخلاصة: الإنسولين ضرورة لا غنى عنها للنوع الأول، أما في النوع الثاني فالأدلة تدعو إلى التحفظ في الجرعات وتفضيل الميتفورمين والتدخل الغذائي قبل تكثيف الإنسولين، لا إلى رفض الإنسولين كاملًا كما يطرح العوضي.

verbatim according to source. Translation by the project; the Arabic wording is authoritative.

Translation

Archive conclusion: insulin is indispensable in type 1 diabetes; in type 2 diabetes, evidence supports caution with intensive dosing, prioritising metformin, weight loss and dietary change before insulin escalation, and aiming for moderate rather than near-normal HbA1c; this is not the same as rejecting insulin.

Origin

Source status: Archive editors
Attribution: Archive editors (not Elawady)
Origin: https://eltayebat.com/rule/insulin-injections/
Attribution uncertainty: Editorial narrative and study selection written by the archive operators.

Population concerned: People with diabetes
Geographic restriction by Elawady: none found

Scientific assessment

Mostly true – Correct at its core, but with limitations or minor inaccuracies.

Certainty of evidence: high – Further research is very unlikely to change the assessment.

1. What was claimed?

Insulin essential in type 1; caution and moderation in type 2; not a rejection of insulin.

2. What is demonstrably correct?

ADA 2026: an HbA1c goal <7% is appropriate for many adults, less stringent goals for people with significant limitations, and hypoglycaemia-causing drugs (insulin, sulfonylureas) should be deintensified where risks outweigh benefits (I-INS-10). Metformin reduced diabetes-related endpoints and mortality in overweight patients in UKPDS 34 (I-ODD-01). Insulin is essential in type 1 diabetes (I-ODD-16). This archive conclusion contradicts Elawady's own position that insulin should be avoided.

3. What is wrong or exaggerated?

The archive omits that current guidelines recommend SGLT2 inhibitors or GLP-1 receptor agonists independently of HbA1c in people with cardiovascular disease, heart failure or kidney disease (I-ODD-16, I-ODD-17), and that insulin should be started regardless of other therapy when HbA1c >10%, glucose >=300 mg/dL or catabolic features are present (I-ODD-16).

4. What remains unclear?

Which HbA1c target and which order of drugs is best for an individual depends on age, other diseases, hypoglycaemia risk and preferences; guidelines give ranges rather than one rule. Whether the archive's emphasis on caution with insulin leads readers to delay insulin when it is needed was not studied.

5. Which studies support it?

A-INS-01, A-INS-19, I-INS-10, I-ODD-01, I-ODD-16, I-ODD-17, I-INS-122 (RCTs: insulin in T2D does not change mortality but increases severe hypoglycaemia), I-INS-133 ('lifelong insulin therapy is essential in type 1 diabetes'), I-INS-131 (youth T2D: maximise non-insulin therapy; reduce insulin when goals met), I-DIAB-115 (NICE: remission programmes).

6. Which studies contradict it?

None material.

7. What applies to Germany and Europe?

European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.

8. What is known about Egypt?

Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.

9. What practical conclusion is appropriate?

This is a reasonable summary and differs fundamentally from the claims attributed to Elawady.

Assessment details

Rationale for certainty of evidence: Consistent with ADA Standards 2026 and ADA/EASD consensus. Not fully “True” because current guidelines also prioritise SGLT2 inhibitors and GLP-1 receptor agonists with proven cardiorenal benefit and recommend early insulin when glucose is very high or catabolic features are present.
Source quality: Archive editorial; it explicitly distances itself from Elawady's rejection of insulin.
Regional transferability: Universal.
Regional scope of the claim: general (biological/medical)
Last reviewed: 26 October 2026 provisional

Scientific evidence in detail

Scientifically well supported – The claim agrees with consistent, high-quality evidence.

Research question: Is the archive's conclusion correct that insulin is indispensable in type 1 diabetes and that in type 2 diabetes caution with intensive insulin, prioritising metformin, weight loss and diet, and moderate HbA1c targets are evidence-based?

Research question in detail (PICO)

Population

People with type 1 and type 2 diabetes

Intervention or exposure

Insulin strategy as summarised by the archive

Comparison

Current guidelines

Geographic scope

universal biology

Outcomes

Agreement with guidelines
Mortality and hypoglycaemia with insulin in T2D

Study results as reported by the authors. Our assessment follows below.

What speaks for the claim?

European and US consensus 2026 on type 1 diabetes in adults

Holt RIG et al.. Diabetologia 2026 · PMID 42747450 · DOI 10.1007/s00125-026-06833-z Guideline / position statementfull text checkednewly added

ADA/EASD 2026 T1D consensus.

Actual result
'Lifelong insulin therapy is essential in type 1 diabetes'.
Methodological quality
high (guideline)
Relevance
direct

Original publication
Insulin in type 2 diabetes: what randomised trials show

Erpeldinger S et al.. BMC Endocr Disord 2016 · PMID 27391319 · DOI 10.1186/s12902-016-0120-z Meta-analysisabstract checkednewly added

RCT meta-analysis of insulin in T2D.

Actual result
No mortality effect; severe hypoglycaemia RR 1.70.
Methodological quality
high
Relevance
direct
Limitations
Trials to 2013.

Original publication
ADA guideline 2026: blood sugar goals and emergencies

American Diabetes Association Professional Practice Committee for Diabetes* . Diabetes Care 2026 · PMID 41358894 · DOI 10.2337/dc26-S006 Guideline / position statementfull text checked

ADA 2026 section 6.

Actual result
A1C <7% for many; less stringent goals where appropriate; deintensify hypoglycaemia-causing drugs.
Methodological quality
high (guideline)
Relevance
direct

Original publication

What speaks against the claim?

No high-quality evidence against the claim was found.

What does the overall evidence say?

Editorial assessment based on the studies above – not itself a study result.

Which position is better supported?

The archive's conclusion matches guidelines; it omits that SGLT2 inhibitors/GLP-1 RAs are prioritised for cardiorenal protection and that insulin is indicated early when glucose is very high or catabolic.

Why some studies weigh more

Guidelines and RCT meta-analysis.

Is a causal relationship established? Not applicable Assessment of a summary statement.

Remaining uncertainty

Individual targets vary.

Justified conclusion

Mostly true.

Does this depend on the country?

General biological effects: Insulin physiology, autoimmune type 1 diabetes and ketoacidosis are universal human biology.
Eating habits: Egyptian and European diets differ, but no dietary pattern replaces insulin in insulin-deficient diabetes.
Origin of the food: Not relevant.
Contaminants: Not relevant.
National production conditions: Not relevant.
Legal rules: Insulin is an essential medicine (WHO list) in Egypt and the EU; prescription rules not relevant to the scientific question.
Actual monitoring data: Egyptian/Middle Eastern data show severe DKA is common at presentation in children (I-INS-115, I-INS-114); no data on outcomes among Tayebat followers.

A regional difference that changes the conclusion is not supported by robust data.

Statistical re-check

CI symmetry – Mortality RR 0.99 (0.92-1.06) symmetric recalculated

Certainty of the overall evidence (GRADE, simplified)

Main outcome: Agreement of the archive conclusion with guideline evidence
Starting level: high (randomised trials)
Result: high

Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.

Clinical guidelines and official statements checked

ADA/EASD: The management of type 1 diabetes in adults: updated 2026 consensus report (2026) · Original publication
'Lifelong insulin therapy is essential in type 1 diabetes'; all individuals need glucose and ketone testing supplies; insulin omission or under-dosing is a DKA precipitant.
ADA: 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026) · Original publication
People at risk for DKA should have ketone testing tools and sick-day advice; people on intensive insulin therapy should not stop or hold basal insulin even if not eating; caution with near-normal A1C goals in long-standing T2D using hypoglycaemia-prone drugs (ACCORD).
ADA: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (I-ODD-16) (2026) · Original publication
'Insulin treatment is essential for individuals with type 1 diabetes'; insulin to be considered in T2D when A1C >10%, glucose >=300 mg/dL or catabolic features (as recorded for I-ODD-16).
ADA: 14. Children and Adolescents: Standards of Care in Diabetes-2026 (2026) · Original publication
For type 1 diabetes 'insulin therapy is paramount'; rec 14.36: start insulin in ketoacidosis; thyroid screening because of autoimmune clustering; in youth T2D maximise non-insulin therapy and consider reducing insulin when goals are met (14.39-14.40).
NICE: NG28 Type 2 diabetes in adults: management (last updated 18 February 2026) (2026) · Original publication
Low-energy and very-low-energy diets via the NHS Type 2 Diabetes Path to Remission Programme (1.3.4); evidence on stopping/switching medicines is limited (research recommendation).

Search strategy

Documented literature searches for this review (search strings in the original database syntax).

Database	Date	Search	Looking for	Hits
PubMed	26 October 2026	`"type 2 diabetes" AND (deintensification OR "de-intensification") AND insulin AND (older OR hypoglycemia) AND (guideline OR consensus)`	both directions	4
PubMed	26 October 2026	`Erpeldinger S[au] AND insulin`	both directions	2
Guideline websites (NICE)	26 October 2026	`Fetched https://www.nice.org.uk/guidance/ng28/chapter/Dietary-advice-and-interventions (+ Insulin-based-treatments, Individualised-care)`	guidelines	3
Springer (publisher full text)	26 October 2026	`Fetched https://link.springer.com/article/10.1007/s00125-026-06833-z (ADA/EASD 2026 T1D consensus)`	guidelines	1
PMC (publisher full text)	26 October 2026	`Fetched ADA Standards of Care 2026 sections 2, 6, 8, 10, 14, 16 at pmc.ncbi.nlm.nih.gov/articles/PMC12690183, PMC12690178, PMC12690172, PMC12690187, PMC12690182, PMC12690180`	guidelines	6

How deeply was this checked?

10 linked studies: 6 checked in full text (0 of them with a structured risk-of-bias assessment), 4 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.

Last scientific review: 26 October 2026

History of the verdict

25 October 2026 · Phase 1 · Initial assessment: Mostly true (high)
26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: Mostly true (high)
New guideline and meta-analytic evidence confirm the archive's summary.
New sources: I-INS-122 I-INS-131 I-INS-133 I-DIAB-115

In plain language

The archive's own summary says that insulin is life-saving in type 1 diabetes and that in type 2 diabetes doctors should avoid pushing blood sugar too low and should start with metformin, weight loss and diet. This matches current medical guidelines, which also recommend newer drugs that protect the heart and kidneys.

Studies on this claim

Studies supporting the claim (10)

Very aggressive blood sugar lowering in high-risk type 2 diabetes

Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743

Randomised controlled trialcited by the Tayebat archivefull text checked★ key study

Pushing HbA1c below 6% increased deaths by about one-fifth and did not reduce heart attacks or strokes significantly.

Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

Original publication · Scientific details

Study explained simply
What did the researchers want to find out?
Does targeting a normal HbA1c (<6.0%) reduce cardiovascular events in type 2 diabetes with high cardiovascular risk?
How was the study done?
Multicentre randomised controlled trial (open-label treatment strategies), mean 3.5 years of intensive therapy
How many people, animals or samples were studied?
10,251; Type 2 diabetes, mean age 62.2, median HbA1c 8.1%, established CVD or additional risk factors
What was actually found?
More deaths (HR 1.22) and more severe hypoglycaemia with intensive therapy; primary CV outcome not significantly reduced.
How large was the observed effect?
HR 1.22 (1.01-1.46) all-cause death; HR 0.90 (0.78-1.04) primary outcome
What do the results mean in everyday life?
Very strict sugar targets are not good for everyone, especially older people with heart disease.
What are the study's limitations?
Strategy trial: cannot attribute harm to a specific drug; Intensive arm stopped early; High-risk population; not generalisable to early diabetes
What does it say about Elawady's specific claim?
Core evidence that near-normal HbA1c targets can harm high-risk type 2 patients (C-INS-04).
Do the results apply to Germany and Europe?
Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
What can explicitly not be concluded from this study?
That insulin specifically caused the deaths, or that lowering high glucose to moderate targets is harmful.
Scientific details →
Adding metformin to insulin

Wulffelé MG et al.. Diabetes Care 2002 · PMID 12453950 · DOI 10.2337/diacare.25.12.2133

Randomised controlled trialcited by the Tayebat archiveabstract checked

Metformin improved sugar control and reduced insulin need and weight gain.

Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

Original publication · Scientific details

Study explained simply
What did the researchers want to find out?
Metformin added to intensive insulin in type 2 diabetes
How was the study done?
Double-blind placebo-controlled RCT
How many people, animals or samples were studied?
390; Insulin-treated type 2 diabetes
What was actually found?
Better control, less insulin, less weight gain.
How large was the observed effect?
GHb -0.7%
What do the results mean in everyday life?
Combination lowers insulin needs.
What are the study's limitations?
Short duration; Dropouts higher with metformin
What does it say about Elawady's specific claim?
Supports C-INS-11; context for C-INS-10.
Do the results apply to Germany and Europe?
Dutch data.
What can explicitly not be concluded from this study?
That insulin can be stopped.
Scientific details →
ADA guideline 2026: blood sugar goals and emergencies

American Diabetes Association Professional Practice Committee for Diabetes* . Diabetes Care 2026 · PMID 41358894 · DOI 10.2337/dc26-S006

Guideline / position statementindependent cross-checkfull text checked★ key study

Most adults should aim for HbA1c below 7%, avoid low sugar, and measure ketones when at risk.

Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

Original publication · Scientific details

Study explained simply
What did the researchers want to find out?
Glycaemic goals, hypoglycaemia and hyperglycaemic crises
How was the study done?
Clinical practice guideline (ADA Standards of Care 2026, Section 6)
How many people, animals or samples were studied?
not applicable; People with diabetes
What was actually found?
Individual targets; do not stop basal insulin when not eating.
How large was the observed effect?
not applicable
What do the results mean in everyday life?
Moderate targets and safety rules.
What are the study's limitations?
US-centred; Partially read
What does it say about Elawady's specific claim?
Supports C-INS-04, C-INS-11; contradicts C-FAST-01, C-FAST-03, C-DIAB-02.
Do the results apply to Germany and Europe?
Consistent with EASD guidance.
What can explicitly not be concluded from this study?
Not applicable.
Scientific details →
Metformin in overweight type 2 diabetes (UKPDS 34)

UKPDS Group. Lancet 1998 · PMID 9742977

Randomised controlled trialindependent cross-checkabstract checked★ key study

Metformin reduced deaths from any cause by about a third over 10 years.

Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

Original publication · Scientific details

Study explained simply
What did the researchers want to find out?
Intensive control with metformin in overweight type 2 diabetes
How was the study done?
RCT within UKPDS (UKPDS 34)
How many people, animals or samples were studied?
753 (main comparison); Overweight newly diagnosed type 2 diabetes, mean age 53
What was actually found?
Mortality -36%.
How large was the observed effect?
RR reduction 36% (9-55)
What do the results mean in everyday life?
Metformin is protective.
What are the study's limitations?
Small arms; Open-label; Conflicting supplementary result
What does it say about Elawady's specific claim?
Contradicts C-ODD-01, C-ODD-06; supports C-INS-11.
Do the results apply to Germany and Europe?
UK.
What can explicitly not be concluded from this study?
Effects in non-overweight patients.
Scientific details →
ADA guideline 2026: diabetes medicines

American Diabetes Association Professional Practice Committee for Diabetes*. Diabetes Care 2026 · PMID 41358900 · DOI 10.2337/dc26-S009

Guideline / position statementindependent cross-checkfull text checked★ key study

Insulin is essential in type 1 diabetes; SGLT2/GLP-1 drugs are recommended for heart and kidney protection; side effects listed.

Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

Original publication · Scientific details

Study explained simply
What did the researchers want to find out?
Pharmacologic glycaemic treatment
How was the study done?
Clinical practice guideline (ADA Standards of Care 2026, Section 9)
How many people, animals or samples were studied?
not applicable; People with type 1 and type 2 diabetes
What was actually found?
See results.
How large was the observed effect?
not applicable
What do the results mean in everyday life?
Medicines chosen by benefit-risk.
What are the study's limitations?
Partially read
What does it say about Elawady's specific claim?
Contradicts C-INS-07, C-INS-10, C-ODD-06; supports C-ODD-07, C-INS-11.
Do the results apply to Germany and Europe?
Consistent with ADA/EASD consensus.
What can explicitly not be concluded from this study?
Not applicable.
Scientific details →
ADA/EASD consensus 2022

Davies MJ et al.. Diabetes Care 2022 · PMID 36148880 · DOI 10.2337/dci22-0034

Guideline / position statementindependent cross-checkabstract checked

Weight management plus heart- and kidney-protective drugs are central to type 2 diabetes care.

Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

Original publication · Scientific details

Study explained simply
What did the researchers want to find out?
Management of hyperglycaemia in type 2 diabetes
How was the study done?
ADA/EASD consensus report based on systematic examination of publications since 2018
How many people, animals or samples were studied?
not applicable; Adults with type 2 diabetes
What was actually found?
Cardiorenal protection and weight focus.
How large was the observed effect?
not applicable
What do the results mean in everyday life?
Guideline direction.
What are the study's limitations?
Abstract only read
What does it say about Elawady's specific claim?
Contradicts C-ODD-06; supports C-INS-11.
Do the results apply to Germany and Europe?
EASD co-authored; directly applicable to EU.
What can explicitly not be concluded from this study?
Not applicable.
Scientific details →
Insulin in type 2 diabetes: what randomised trials show

Erpeldinger S et al.. BMC Endocr Disord 2016 · PMID 27391319 · DOI 10.1186/s12902-016-0120-z

Meta-analysisindependent cross-checkabstract checked★ key study

In 20 trials with 18,599 people, insulin did not change the risk of death but caused more severe low blood sugar.

No hard-outcome benefit and more hypoglycaemia in T2D: supports caution with insulin escalation.

Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

Original publication · Scientific details

Study explained simply
What did the researchers want to find out?
Summarise RCTs of insulin in T2D.
How was the study done?
Meta-analysis of 20 RCTs.
How many people, animals or samples were studied?
18,599 patients.
What was actually found?
Mortality unchanged; severe hypoglycaemia +70%.
How large was the observed effect?
RR 0.99 death; 1.70 severe hypoglycaemia.
What do the results mean in everyday life?
Insulin does not kill, but low sugar is a real risk; use it carefully.
What are the study's limitations?
Older trials; heterogeneity.
What does it say about Elawady's specific claim?
Refutes 'insulin doubles mortality'; supports caution.
Do the results apply to Germany and Europe?
Applicable.
What can explicitly not be concluded from this study?
Cannot address insulin in type 1 diabetes, where it is essential.
Scientific details →
European and US consensus 2026 on type 1 diabetes in adults

Holt RIG et al.. Diabetologia 2026 · PMID 42747450 · DOI 10.1007/s00125-026-06833-z

Guideline / position statementindependent cross-checkfull text checked★ key study

Lifelong insulin is essential in type 1 diabetes, and everyone with type 1 diabetes should be able to test glucose and ketones.

Confirms the archive's 'insulin indispensable in type 1'.

Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

Original publication · Scientific details

Study explained simply
What did the researchers want to find out?
Update guidance on adult T1D care.
How was the study done?
Consensus report.
How many people, animals or samples were studied?
Not applicable.
What was actually found?
Insulin lifelong and essential; ketone testing for all.
How large was the observed effect?
Not applicable.
What do the results mean in everyday life?
People with type 1 diabetes must never stop insulin.
What are the study's limitations?
Consensus.
What does it say about Elawady's specific claim?
Contradicts C-INS-07/09/10; supports C-INS-11.
Do the results apply to Germany and Europe?
European (EASD) guidance.
What can explicitly not be concluded from this study?
Not applicable.
Scientific details →
US diabetes standards 2026: children and adolescents

American Diabetes Association Professional Practice Committee for Diabetes. Diabetes Care 2026 · PMID 41358890 · DOI 10.2337/dc26-S014

Guideline / position statementindependent cross-checkfull text checked★ key study

Insulin is essential for children with type 1 diabetes; in youth with type 2 diabetes, insulin can be reduced when goals are met.

Youth T2D: maximise non-insulin therapy; reduce insulin when goals met.

Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

Original publication · Scientific details

Study explained simply
What did the researchers want to find out?
Guide paediatric diabetes care.
How was the study done?
Evidence-graded guideline.
How many people, animals or samples were studied?
Not applicable.
What was actually found?
Insulin paramount in T1D; insulin for ketoacidosis.
How large was the observed effect?
Not applicable.
What do the results mean in everyday life?
Children with type 1 diabetes need insulin.
What are the study's limitations?
Guideline.
What does it say about Elawady's specific claim?
Contradicts C-INS-07; supports C-INS-11.
Do the results apply to Germany and Europe?
European paediatric guidance (ISPAD, NICE NG18) agrees.
What can explicitly not be concluded from this study?
Not applicable.
Scientific details →
UK guideline on type 2 diabetes in adults

National Institute for Health and Care Excellence (NICE). NICE guideline 2015

Guideline / position statementindependent cross-checkfull text checked★ key study

Low-energy diet remission programmes are part of standard UK care for type 2 diabetes.

Diet/weight-loss remission programmes are standard in UK T2D care.

Does the study support the specific claim? Yes · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

Original publication · Scientific details

Study explained simply
What did the researchers want to find out?
Guide T2D care.
How was the study done?
Guideline.
How many people, animals or samples were studied?
Not applicable.
What was actually found?
Remission programme recommended.
How large was the observed effect?
Not applicable.
What do the results mean in everyday life?
Diet and weight loss come first in type 2 diabetes, under supervision.
What are the study's limitations?
Guideline.
What does it say about Elawady's specific claim?
Supports C-INS-11.
Do the results apply to Germany and Europe?
UK.
What can explicitly not be concluded from this study?
Not applicable.
Scientific details →

Studies contradicting or limiting the claim (0)

No studies in this group.

Studies with mixed or unclear results (0)

No studies in this group.

Regional context

Germany / EU

Egypt

What applies in my country?

General scientific assessment

Mostly true The archive's conclusion broadly matches guidelines and contradicts the rejection of insulin.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

Effects of intensive glucose lowering in type 2 diabetes.. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743
Combination of insulin and metformin in the treatment of type 2 diabetes.. Wulffelé MG et al.. Diabetes Care 2002 · PMID 12453950 · DOI 10.2337/diacare.25.12.2133
6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes* . Diabetes Care 2026 · PMID 41358894 · DOI 10.2337/dc26-S006
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.. UKPDS Group. Lancet 1998 · PMID 9742977
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes*. Diabetes Care 2026 · PMID 41358900 · DOI 10.2337/dc26-S009
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).. Davies MJ et al.. Diabetes Care 2022 · PMID 36148880 · DOI 10.2337/dci22-0034
Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials.. Erpeldinger S et al.. BMC Endocr Disord 2016 · PMID 27391319 · DOI 10.1186/s12902-016-0120-z
The management of type 1 diabetes in adults. The updated 2026 consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).. Holt RIG et al.. Diabetologia 2026 · PMID 42747450 · DOI 10.1007/s00125-026-06833-z
14. Children and Adolescents: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes. Diabetes Care 2026 · PMID 41358890 · DOI 10.2337/dc26-S014
NICE guideline NG28: Type 2 diabetes in adults: management. National Institute for Health and Care Excellence (NICE). NICE guideline 2015

← Back to overview